Wednesday, November 13, 2024 11:34:42 AM
So flat YOY revenue (although still tracking in the 800k-1MM range for the year), COGS continues to be more in line with a real company (ie, the illusory profits of the past have vanished, but we finally see money being spent on SG&A, R&D, etc.).
Not overly impressive, but a massive step up from previous years and further demonstration of the maturation of the organization.
I expect a lot of folks will continue to sit on their hands until we see evidence of ABBIE action in the fins.
Not overly impressive, but a massive step up from previous years and further demonstration of the maturation of the organization.
I expect a lot of folks will continue to sit on their hands until we see evidence of ABBIE action in the fins.
Recent SHMN News
- SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery • ACCESS Newswire • 11/06/2025 02:30:00 PM
- SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development • ACCESS Newswire • 11/04/2025 02:30:00 PM
